The scrip of Aurobindo Pharma increased 5.9 per cent to close at Rs 297.75 after its Australian subsidiary received the approval from the Therapeutic Goods Administration to launch a cholesterol-lowering drug.
The approval from the Australian regulatory body will help the company to launch the tablets in strengths ranging from 5mg to 80mg. The stock made an intraday high of Rs 303 and a low of Rs 277.1, with trading volumes of 2.66 lakh shares. The scrip made a 52-week high of Rs 360 and a low of Rs 101.6.